SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of Earliest Event Reported): November 16, 2004


                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
               (Exact Name of Registrant as Specified in Charter)


          DELAWARE                  000-33167                   84-0448400
(State or Other Jurisdiction       (Commission                (I.R.S. Employer
      of Incorporation)            File Number)              Identification No.)


                   17700 CASTLETON STREET, SUITE 589
                     CITY OF INDUSTRY, CALIFORNIA                  91748
               (Address of Principal Executive Offices)          (Zip Code)


                                 (626) 964-3232
              (Registrant's Telephone Number, Including Area Code)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]      Written  communications  pursuant to Rule 425 under the  Securities Act
         (17 CFR 230.425)

[ ]      Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

[ ]      Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
         Exchange Act (17 CFR 240.14d-2(b))

[ ]      Pre-commencement  communications  pursuant to Rule  13e-4(c)  under the
         Exchange Act (17 CFR 240.13e-4(c))





ITEM 2.02. - RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 7.01. - REGULATION FD DISCLOSURE

         On November 16, 2004,  Kiwa Bio-Tech  Products Group  Corporation  (the
"Registrant")  issued a press release  regarding  its financial  results for the
quarter  and nine  months  ended  September  30, 2004 and its outlook for fourth
quarter of fiscal 2004 results.  A copy of the press release is attached  hereto
as Exhibit 99.1 and is incorporated herein by this reference.

         The information in this report shall not be deemed "filed" for purposes
of Section 18 of the  Securities  Exchange  Act of 1934,  nor shall it be deemed
incorporated  by reference in any filing under the Securities Act of 1933 or the
Securities  Exchange  Act of 1934,  except  as shall be  expressly  set forth by
specific reference in such a filing.


ITEM-9.01. - FINANCIAL STATEMENTS AND EXHIBITS.

         (a)      Financial Statements of business acquired.

                  None.

         (b)      Pro forma Financial Information.

                  None.

         (c)      Exhibits.

                  99.1     Press Release dated  November 16, 2004,  published by
                           the Registrant.


                                       2



                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                   KIWA BIO-TECH PRODUCTS GROUP CORPORATION

Date:    November 16, 2004         By:   /s/ WEI LI                             
                                        ----------------------------------------
                                         Wei Li, Chief Executive Officer


                                       3



                                  EXHIBIT INDEX

Exhibit
Number       Description
-------      -----------
99.1         Press Release dated November 16, 2004, published by the Registrant.


                                       4